DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20200908

Comparison of safety and efficacy of Ormeloxifene and Norethisterone acetate in the treatment of heavy menstrual bleeding

Sunil Kumar Juneja, Pooja Tandon, Gagandeep Kaur

Abstract


Background: Menorrhagia (menstrual blood loss more than 80% per cycle) affects 10-33% of women at some stage of their lives. Medical management is the first line of therapy for menorrhagia (heavy menstrual bleeding: HMB). Progestins have been found to be very effective in the management of heavy menstrual bleeding especially during acute episodes, norethisterone acetate being widely used for the same. Ormeloxifene is a new drug with promising results in managing HMB. The study was undertaken to compare the efficacy, safety and acceptability of Ormeloxifene /Norethisterone acetate in the medical management of heavy menstrual bleeding.

Methods: This was a retrospective study conducted from January 2016 till December 2018 in which 98 women of reproductive age group presented with abnormal uterine bleeding without any organic, systematic and iatrogenic causes. The patients were divided into 2 groups. Those wanting contraception along with control of HMB were assigned to Group O and given Ormeloxifene and others were given norethisterone (Group N). The primary outcomes measured were menstrual blood loss assessed subjectively by patients and ultrasonography for endometrial thickness. The secondary outcomes measured were acceptability and side effects of Ormeloxifene and norethisterone.

Results: There is a significant reduction in menstrual blood loss as evidenced by the history of patients recorded on follow up and there was a significant reduction in the endometrial thickness as evidenced on follow up scan at the end of 3-4 months. no major side effects were observed with both the drugs.

Conclusions: Ormeloxifene in comparison to norethisterone acetate with its effectiveness, significant results, convenient dosages schedule and no major side effects is an effective and safe alternative medical management of HMB.


Keywords


Heavy menstrual bleeding, Norethisterone, Medical therapy, Ormeloxifene

Full Text:

PDF

References


Marsh EE, Brocks ME, Ghant MS, Recht HS, Simon M. Prevalence and knowledge of heavy menstrual bleeding among African American women. Int J Gynecol Obstet. 2014;125(1):56-9.

Vilos GA, Lefebvre G, Graves GR. Guidelines for the management of abnormal uterine bleeding. SOGC clinical practice guidelines. J Obstet Gynaecol Canada. 2001;106:1-6.

Harlow SD, Campbell OMR. Menstrual dysfunction: a missed opportunity for improving reproductive health in developing countries. Reprod Health Matters. 2000;8(15):142-7.

Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA. The association of obesity with infertility and related menstural abnormalities in women. Int J Obes. 1979;3(1):57-73.

Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol. 2000;79:169-17.

Bhargava VL. Textbook of Gynaecology ANE Books. 2nd ed; 2009:109.

Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update. 2002;8(1):60-7.

Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008;63(3):163-81.

Doshi HU, Kriplani A. Clinical cases in Obstetrics and Gynaecology, 1st ed; 2003:250-251.

Samuel NC, Clark TJ. Future research into abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2007;21(6):1023-40.

Shravage J, Mekhala D, Bellad MB, Ganachari MS, Dhumale HA. Ormeloxifene versus medroxyprogesterone Acetate (MPA) in the treatment of dysfunctional uterine bleeding: a double- blind randomized controlled trial. JSAFOG 2011;3(1):21-24.

Jacob KJ, Mini, Deepak AV. A comparative study on the effectiveness of ormeloxifene versus norethisterone in the management of perimenopausal dysfunctional uterine bleeding. JS Asian Fed Obstet Gynecol. 2015;2(7):87-92.